"Pyrrolidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH.
| Descriptor ID |
D011759
|
| MeSH Number(s) |
D03.383.773
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrrolidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrrolidines".
This graph shows the total number of publications written about "Pyrrolidines" by people in this website by year, and whether "Pyrrolidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 2 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 3 | 1 | 4 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 3 | 4 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 4 | 3 | 7 |
| 2016 | 1 | 3 | 4 |
| 2017 | 0 | 4 | 4 |
| 2018 | 2 | 3 | 5 |
| 2019 | 0 | 2 | 2 |
| 2020 | 4 | 2 | 6 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrrolidines" by people in Profiles.
-
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results. Blood Adv. 2024 03 26; 8(6):1515-1528.
-
Synaptic Loss in Spinocerebellar Ataxia Type 3 Revealed by SV2A Positron Emission Tomography. Mov Disord. 2023 06; 38(6):978-989.
-
How I manage anemia related to myelofibrosis and its treatment regimens. Ann Hematol. 2023 Apr; 102(4):689-698.
-
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022 07 26; 6(14):4147-4156.
-
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. Br J Haematol. 2022 07; 198(2):317-327.
-
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study. Hepatology. 2021 07; 74(1):19-27.
-
Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Can J Ophthalmol. 2022 02; 57(1):e6-e10.
-
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat Commun. 2021 04 01; 12(1):2016.
-
A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation. Brief Bioinform. 2021 03 22; 22(2):1476-1498.